Getting it first versus getting it right: weighing the value of and evidence for progression-free survival as a surrogate endpoint for overall survival in glioblastoma.

Conflict of interest statement. Kelong Han is an employee of Genentech and holds stock in F. Hoffmann – La Roche. Melanie Ren was an employee of Genentech at the time the manuscript was written. Wolfgang Wick has acted as a consultant for F. Hoffmann–La Roche, Eli Lilly (uncompensated), and MSD and has received research support from Apogenix, Boehringer Ingelheim, Eli Lilly, and MSD. Lauren Abrey is an employee of F. Hoffmann – La Roche and holds stock in F. Hoffmann–La Roche. Asha Das is an employee of Genentech and holds stock in F. Hoffmann–La Roche. Jin Jin is an employee of Genentech and holds stock in F. Hoffmann – La Roche and Eli Lilly. David A. Reardon has received remuneration (other than research funding, honoraria, and consultancy fees) from F. Hoffmann – La Roche/Genentech and Merck & Co.